Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668512 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Injection Of Alpha-Gal Glycosphingolipids
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00668512 is a Phase 1 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 12 participants.
The verdict
NCT00668512, a Phase 1 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase I pilot study to evaluate the toxicity of two intra-tumoral injections of GSL alpha-GAL in patients with advanced or metastatic cutaneous melanoma. Patients who have failed standard therapies or are not eligible for standard treatment will be eligible for this study.
Interventions
- BIOLOGICAL Antimelanoma injection of GSL alpha-Gal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-03 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668512
The ClinicalTrials.gov registry entry for NCT00668512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antimelanoma injection of GSL alpha-Gal is the first listed.
NCT00668512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668512 about?
NCT00668512 is a clinical study titled "Intratumoral Injection Of Alpha-Gal Glycosphingolipids". This is a Phase I pilot study to evaluate the toxicity of two intra-tumoral injections of GSL alpha-GAL in patients with advanced or metastatic cutaneous melanoma. Patients who have failed standard therapies or are not eligible for standard treatment will be eligible for this study.
What is the current status of trial NCT00668512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00668512?
The interventions under investigation include: Antimelanoma injection of GSL alpha-Gal (BIOLOGICAL).
Who is sponsoring clinical trial NCT00668512?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.